Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.45 |
| ▸ | F3 | P13726 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | PRKCB | P05771 | 3/20 | 0.41 |
| ▸ | PRKCA | P17252 | 2/20 | 0.41 |
| ▸ | PRKCH | P24723 | 2/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5879143 | 0.88 | IDH1 (0.46) | GPR84IDO1CAMK2DPRKCBPRKCA | |
| SCHEMBL5879259 | 0.82 | KDM4E (0.44) | HTR2AIDO1CAMK2DSLC6A4PRKCB | |
| SCHEMBL5879255 | 0.82 | IGF1R (0.50) | GPR84HTR2AMAP3K14IDO1CAMK2D | |
| SCHEMBL5879151 | 0.82 | BRAF (0.44) | HTR2ACAMK2DPRKCBPRKCAPRKCH | |
| SCHEMBL5879171 | 0.82 | CLK1 (0.45) | CAMK2DPRKCBPRKCAPRKCHPRKCE | |
| SCHEMBL5879252 | 0.82 | PDGFRB (0.50) | GPR84HTR2AIDO1CAMK2DSLC6A4 | |
| SCHEMBL7824032 | 0.81 | CAMK2D (0.60) | F7F3GPR84HTR2ACAMK2D | |
| SCHEMBL5879148 | 0.79 | KDR (0.57) | GPR84MAP3K14IDO1CAMK2DSLC6A4 | |
| SCHEMBL10433699 | 0.79 | HTR3E (0.42) | HTR2ACAMK2DPRKCBPRKCAPRKCH | |
| SCHEMBL10433674 | 0.79 | JAK2 (0.46) | CAMK2DPRKCBPRKCAPRKCHPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151108-B2 | Anticarcinogenic, antiproliferative, and antitumor agents | LES LABORATORIES SERVIER (FR) | 2006-12-19 | — | — | US | disclosed |
| US-7129250-B2 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2006-10-31 | — | — | US | disclosed |
| EP-1411057-B1 | [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-11-04 | — | — | US | disclosed |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-05-27 | — | — | US | disclosed |
| US-20040077672-A1 | Anticarcinogenic, antiproliferative, and antitumor agents | LES LABORATOIRES SERVIER (FR) | 2004-04-22 | — | — | US | disclosed |
| EP-1411057-A1 | [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2004-04-21 | — | — | EP | disclosed |
| EP-1283836-A2 | NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS | Aegera Therapeutics Inc. (CA) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001087887-A2 | NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2001-11-22 | — | — | WO | disclosed |
| EP-0397060-A2 | Maleinimide derivatives and their use as medicines | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | NLN, MKI67, BDNF | F7 4763/4885F3 4419/4885GPR84 3518/4885 |
| US-20040077672-A1 | Anticarcinogenic, antiproliferative, and antitumor agents | XDH, TOP2A, TOP1 | F7 3634/4885F3 3195/4885GPR84 3998/4885 |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | MKI67, NLN, BDNF | F7 4746/4885F3 4386/4885GPR84 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.